January 10, 2024 at 7:30 a.m.
U.S. Department of Health and Human Services
This winter, in addition to the COVID-19 and flu vaccines, FDA-approved respiratory syncytial virus immunizations are now available for the first time. With this new vaccine, you can have the strongest protection yet to fight the viruses responsible for the majority of fall and winter hospitalizations — flu, COVID-19 and RSV.
Like last year, RSV cases are on the rise — causing lower respiratory tract disease, and overwhelming doctors’ offices and hospitals with infants, at-risk patients and older adults. It leads to an estimated 60,000-160,000 hospitalizations and 6,000- 10,000 deaths annually among adults ages 65 years and older. For children under 5, RSV causes approximately 58,000-80,000 hospitalizations and 100-300 deaths.